Chronic HIV‐1 Tat action induces HLA‐DR downregulation in B cells: A mechanism for lymphoma immune escape in people living with HIV

• Published in: Journal of medical virology Vol. 96; no. 2; pp. e29423 - n/a
• Main Authors: Shmakova, Anna, Hugot, Coline, Kozhevnikova, Yana, Schwager (Karpukhina), Anna, Tsimailo, Ivan, Gérard, Laurence, Boutboul, David, Oksenhendler, Eric, Szewczyk‐Roszczenko, Olga, Roszczenko, Piotr, Buzun, Kamila, Sheval, Eugene V., Germini, Diego, Vassetzky, Yegor
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2024
• Subjects: Antiretroviral agents; Antiretroviral therapy; B cells; B-Lymphocytes; CD4 antigen; CD4+ T cells; Deregulation; Down-Regulation; Drb1 protein; EBV; Epstein-Barr virus; Epstein-Barr Virus Infections; Gene expression; Gene sequencing; Genes; Herpesvirus 4, Human - genetics; Histocompatibility antigen HLA; HIV; HIV Infections - genetics; HIV-1 - genetics; HIV‐1; HLA-DRB1 Chains; Human immunodeficiency virus; Humans; Immunosurveillance; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Major histocompatibility complex; Malignancy; MHC class II; NF‐кB pathway; RNA‐sequencing; Sequence analysis; Tat; tat Gene Products, Human Immunodeficiency Virus - genetics; Tat protein; HIV-1; RNA-sequencing; Tat; EBV; B cells; CD4+ T cells; MHC class II; NF-кB pathway

Despite the success of combination antiretroviral therapy, people living with human immunodeficiency virus (HIV) still have an increased risk of Epstein−Barr virus (EBV)‐associated B cell malignancies. In the HIV setting, B cell physiology is altered by coexistence with HIV‐infected cells and the ch...